Page 28 - ARNM-3-1

Advances in Radiotherapy
& Nuclear Medicine Chinese Expert Consensus for LACC

Adverse reactions/events 36.7% of patients experienced grade ≥3 adverse events (26.5% with grade 3, 10.2% with grade 4) Similar safety profiles Higher incidence of neutropenia (68% vs. 44%), hypertension (16% vs. 2%), and infections (50% vs. 18%) noted in the experimental group Similar safety profiles Well-tolerated by most patients Similar safety profiles Majority of drug-related adverse reactions were Grades 1–2 Similar s

3-year OS, DFS, and LRF of 81.3%, 68.7%, and 23.2%, 1-year PFS 91.4% vs. 82.1%; 2-year PFS 80.8% vs. 63.5% 2-year OS 83% vs. 87%; 2-year DFS 63% vs. 76% 5-year PFS rate and OS rate 57.5% and 58.5% respectively ORR 86.3% vs. 76.3% CRR 42.6%, PRR 45.0% Significant improvements in experimental group CRR, ORR, and 3-year OS

Efficacy respectively CRR 83% vs. 65%

Follow‑up (Mo.) 45 22 NA 31 NA Ongoing Ongoing NA

RT EBRT IMRT IMRT EBRT, IMRT EFRT IMRT, VMAT IMRT, VMAT IMRT
No. of cases 60 116 91 78 21 291 122 393 Abbreviations: CRR: Complete response rate; DCR: Disease control rate; DFS: Disease-free survival; DMFS: Distant metastasis-free survival; EBRT: External beam radiotherapy; EFRT: Extended-field radiotherapy; EGFR: Epidermal growth factor receptor; IMRT: Intensity-modulated radiotherapy; LACC: Locally advanced cervical cancer; LRF: Locoregional failure; mOS: Median overall survival; NA:

Table 2. Clinical studies of targeted drugs in combination with CCRT for LACC

Study type Phase II single-arm Phase II randomized controlled Phase II randomized controlled Phase II randomized controlled Phase I study Phase III study Phase II study Meta-analysis

Researcher Schefter et al. 8 Lu et al. 9 Shu et al. 10 De la Rochefordiere et al. 11 Fracasso et al. 12 Wang et al. 13 Qu et al. 14 Yuan et al. 15 adverse events; VEGFR: Vascular endothelial growth factor; VMAT: Volumetric modulated arc therapy.

Drug name Bevacizumab Endostar Endostar Cetuximab Cetuximab Nimotuzumab Nimotuzumab Nimotuzumab

Recombinant human endostatin Recombinant human endostatin Anti-EGFR monoclonal antibody Anti-EGFR monoclonal antibody Anti-EGFR monoclonal antibody Anti-EGFR monoclonal antibody Anti-EGFR monoclonal antibody

Classification Anti-VEGFR

Volume 3 Issue 1 (2025) 20 doi: 10.36922/arnm.4032